0001358403-16-000272.txt : 20160923 0001358403-16-000272.hdr.sgml : 20160923 20160923185524 ACCESSION NUMBER: 0001358403-16-000272 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160921 FILED AS OF DATE: 20160923 DATE AS OF CHANGE: 20160923 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BELLICUM PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001358403 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 201450200 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 BUSINESS PHONE: (832) 384-1100 MAIL ADDRESS: STREET 1: 2130 WEST HOLCOMBE BOULEVARD STREET 2: SUITE 800 CITY: HOUSTON STATE: TX ZIP: 77030 FORMER COMPANY: FORMER CONFORMED NAME: BELLICUM PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moseley Ken CENTRAL INDEX KEY: 0001626895 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36783 FILM NUMBER: 161900754 MAIL ADDRESS: STREET 1: C/O BELLICUM PHARMACEUTICALS, INC. STREET 2: 2130 W. HOLCOMBE BLVD., STE. 800 CITY: HOUSTON STATE: TX ZIP: 77030 4 1 wf-form4_147467131145613.xml FORM 4 X0306 4 2016-09-21 0 0001358403 BELLICUM PHARMACEUTICALS, INC BLCM 0001626895 Moseley Ken C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800 HOUSTON TX 77030 0 1 0 0 Sr. VP and General Counsel Common Stock 2016-09-21 4 M 0 100 7.47 A 444 D Common Stock 2016-09-21 4 S 0 100 20.04 D 344 D Common Stock 2016-09-23 4 M 0 11700 7.47 A 12044 D Common Stock 2016-09-23 4 S 0 11700 20.1024 D 344 D Stock Option (right to buy) 7.47 2016-09-21 4 M 0 100 0 D 2024-11-10 Common Stock 100.0 40817 D Stock Option (right to buy) 7.47 2016-09-23 4 M 0 11700 0 D 2024-11-10 Common Stock 11700.0 29117 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 24, 2015 by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the shares subject to the stock option vest and become exercisable on November 11, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. /s/ Ken Moseley 2016-09-23